Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VSF-173 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| VSF-173 | DRUG | - |
Inclusion Criteria: * Healthy subjects with no medical, psychiatric, or current sleep disorders * Subject must sign a written consent form Exclusion Criteria: * Evidence of excessive daytime sleepiness * History of sleep disorders * Psychiatric or neurological disorders
VSF-173 is an investigational small molecule being developed for the treatment of excessive somnolence, a condition characterized by excessive sleepiness. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
VSF-173 is being developed by Vanda Pharmaceuticals Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol VNDA. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
VSF-173 is in Phase 2 clinical development. It has completed one Phase 2 trial, and it remains an investigational drug that has not been approved for commercial use. Further clinical studies may be needed to establish its safety and effectiveness.
VSF-173 has one completed clinical trial, NCT00467441, which was a Phase 2 study in healthy adult volunteers for the treatment of induced excessive sleepiness. The trial was conducted in France, enrolled 60 participants, and was randomized and double-blind.
No, VSF-173 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development. The completed trial, NCT00467441, was a Phase 2 study, but the drug has not yet received regulatory approval for any indication.